This continuing education activity is managed and accredited by Professional Education Service Group. The information presented in this activity represents the opinion of the author(s) or faculty. Neither PESG, nor any accrediting organization endorses any commercial products displayed or mentioned in conjunction with this activity.

Commercial Support was not received for this activity.

The following relevant financial relationships with commercial interests were disclosed:
Dr. Baum is a member of the Editorial Board of ToxEd.com and Pediatric Emergency Care. A family member is a stock holder in Biogen.

CME Staff Disclosures

Professional Educational Services Group staff has no financial interest or relationships to disclose.

Drug Disclaimer

Drugs with potential therapeutic value are mentioned in this primer. For the purposes of this primer, the following drugs are considered FDA off-label for radiation disaster induced neutropenia:

  • Pegfilgrastim
  • Filgrastim
  • Sargramostin

A Strategic National Stockpile (SNS) Radiation Working Group has recommended these drugs for use in radiation disaster induced neutropenia, and FDA advisory committees are evaluating this for further consideration as a label change. To follow this evolving preparedness effort, please see http://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/AboutMCMi/ucm443245.htm#rad .

The following drugs may be off-label for pediatric radiation disaster patients depending on the age of the patient not due to the indication:

  • Prussian Blue
  • Cefepime
  • Gancyclovir
  • Valacyclovir
  • Granisetron
  • Loperamide
  • Ciprofloxacin
  • Levofloxacin
  • Fluconazole

Previous Page     Next Page